Colleen Brophy
Affiliations: | Arizona State University, Tempe, AZ, United States |
Area:
Cell Biology, Biomedical EngineeringGoogle:
"Colleen Brophy"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Yim TW, Perling D, Polcz M, et al. (2020) A cell permeant phosphopeptide mimetic of Niban inhibits p38 MAPK and restores endothelial function after injury. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology |
| Yim TW, Perling D, Polcz M, et al. (2020) A cell permeant phosphopeptide mimetic of Niban restores endothelial function and inhibits p38 MAPK activation after vascular injury The Faseb Journal. 34: 1-1 |
| Hocking KM, Evans BC, Komalavilas P, et al. (2018) Nanotechnology Enabled Modulation of Signaling Pathways Affects Physiology in Intact Vascular Tissue. Tissue Engineering. Part A |
| Luo W, Feldman D, McCallister R, et al. (2017) P2X7R antagonism after subfailure overstretch injury of blood vessels reverses vasomotor dysfunction and prevents apoptosis. Purinergic Signalling |
| Osgood MJ, Sexton K, Voskresensky I, et al. (2016) Use of Brilliant Blue FCF during vein graft preparation inhibits intimal hyperplasia. Journal of Vascular Surgery. 64: 471-478 |
| Leaker B, Nicholson G, Petersen C, et al. (2016) LATE-BREAKING ABSTRACT: Effect of inhaled kinase inhibitor on airway inflammation assessed in induced sputum after challenge with inhaled lipopolysaccharide European Respiratory Journal. 48 |
| Evans BC, Hocking KM, Osgood MJ, et al. (2015) MK2 inhibitory peptide delivered in nanopolyplexes prevents vascular graft intimal hyperplasia. Science Translational Medicine. 7: 291ra95 |
| Hocking KM, Luo W, Li FD, et al. (2015) Brilliant blue FCF is a nontoxic dye for saphenous vein graft marking that abrogates response to injury. Journal of Vascular Surgery |
| Osgood MJ, Flynn CR, Komalavilas P, et al. (2013) Cell-permeant peptide inhibitors of vasospasm and intimal hyperplasia. Vascular. 21: 46-53 |
| Muto A, Panitch A, Kim N, et al. (2012) Inhibition of Mitogen Activated Protein Kinase Activated Protein Kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. Vascular Pharmacology. 56: 47-55 |